Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .

NCT ID: NCT05401006

Last Updated: 2022-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-05

Study Completion Date

2023-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acitretin

Patients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .

Group Type ACTIVE_COMPARATOR

Acitretin 25Mg Cap

Intervention Type DRUG

Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients

Narrowband ultraviolet B

Patients will receive Narrowband UVB( 3session /week ) for 3months.

Group Type ACTIVE_COMPARATOR

Narrowband ultraviolet B

Intervention Type RADIATION

Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months

Combination of Narrowband ultraviolet B and Acitretin

Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.

Group Type ACTIVE_COMPARATOR

Acitretin 25Mg Cap

Intervention Type DRUG

Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients

Narrowband ultraviolet B

Intervention Type RADIATION

Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acitretin 25Mg Cap

Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients

Intervention Type DRUG

Narrowband ultraviolet B

Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Narrowband UVB

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with psoriasis diagnosed clinically Aged (15-60).

Exclusion Criteria

* Patient with history of skin cancer.
* Patient with history of photosensitivity.
* Pregnancy and lactation.
* Liver failure.
* Renal failure.
* Patient with psoriatic artheritis.
* Patient with allergy to product or any of its components.
* Patient with poorly controlled dyslipidemia.
* Patient receiving tetracyclines.
Minimum Eligible Age

15 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

South Valley University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fatma Elsayed abd Elfatah Elsayed

Resident doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

South Valley University

Qina, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

209/6/21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nicotinamide in the Treatment of Psoriasis
NCT01763424 COMPLETED PHASE2/PHASE3
Excimer Light in Psoriasis
NCT05283876 COMPLETED NA